Ipsen hands back Parkinson's drug rights to Santhera

French drugmaker Ipsen ($IPN) has a game plan for developing new drugs, and Santhera's ($SANN) Parkinson's disease treatment fipamezole didn't make the cut. Switzerland-based Santhera said that it has regained worldwide rights to the experimental drug from Ipsen and is now looking for a new partner for the program, which is set to enter late-stage studies for treating dyskinesia in Parkinson's patients, Reuters reported. In return for handing back rights to the drug to Santhera for markets outside North America and Japan, Ipsen is expected to get a cut of potential milestones and royalties related to fipamezole. Article

THE LIBRARY: WEBINAR

At first glance, the TMF reference model seems daunting, especially for smaller companies. In this webinar, Kristen Snipes and Missy Lavinder share tips and tricks for making the process manageable based on their own recent experience implementing the model. Register today!